⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769166 | 1.00 | — | — | |
| SCHEMBL14926672 | 0.85 | — | — | |
| SCHEMBL10456918 | 0.78 | — | — | |
| SCHEMBL13050785 | 0.78 | — | — | |
| SCHEMBL8521253 | 0.78 | — | — | |
| SCHEMBL11714973 | 0.78 | — | — | |
| SCHEMBL18032007 | 0.75 | — | — | |
| SCHEMBL5914822 | 0.75 | — | — | |
| SCHEMBL8400598 | 0.75 | — | — | |
| SCHEMBL4557450 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010151232-A1 | METHOD FOR MODIFYING ELECTRICAL PROPERTIES OF CARBON NANOTUBES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-12-29 | — | — | WO | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| EP-4735414-A2 | CHEMICALLY DEGRADABLE AND FUNCTIONALLY MODIFIABLE POLYMERS AND HYDROGELS | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006732-A2 | CHEMICALLY DEGRADABLE AND FUNCTIONALLY MODIFIABLE POLYMERS AND HYDROGELS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-10541151-B1 | Disposable laser/flash anneal absorber for embedded neuromorphic memory device fabrication | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2020-01-21 | — | — | US | disclosed |
| CN-108473499-A | Novel Pyrazolopyrimidine derivative | 诺华股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| WO-2010065996-A1 | MODIFIED CLAY SORBENTS | CRC CARE PTY LTD (AU) | 2010-06-17 | — | — | WO | disclosed |
| US-7635725-B2 | curing ultrahigh molecular weight polyethylenes under pressurization, and heating; oxidation resistance, wear resistance, enhanced stiffness, enhanced tensile strength, a high level of fatigue and crack propagation resistance, and creep resistance | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7468434-B2 | Diazene-bridge crown ether lithium compounds and methods for their use | THE UNIVERSITY OF HONG KONG (CN) | 2008-12-23 | — | — | US | disclosed |
| US-20070298127-A1 | Administering lithium ion-chelated in a crown ether- or aza-crown ether-containing chromene or diazene derivative and a carrier; exposing eye to an external light soure to cause the aza-crown ether or crown ether of a chromene or a diazene compound to release lithium, glaucoma | HONG KONG, UNIVERSITY OF, THE (HK) | 2007-12-27 | — | — | US | disclosed |
| US-20070197679-A1 | Crosslinked polymers | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | disclosed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |